Since the PD-1:PD-L1 axis exerts multiple functions within the tumor environment, combinatorial therapeutic approaches allowing for simultaneous manipulation of T cell priming in secondary lymphoid organs and modulation of effector functions in the highly suppressive tumor microenvironment were therefore suggested early to improve cancer therapy. Here, PDCD1 is linked to neoplasm.